views
Over 85 firms are involved in providing fragment-based drug discovery-related services
Accordingto experts in this field, fragment-based drug discovery solutions havefacilitated the identification of viable pharmacological leads againstotherwise hard to target biomolecules. In fact, many service provider companiesare offering fragment libraries and support to the medical research communityin order to develop an appropriate intervention to treat the illness caused bythe SARS-CoV-2 virus.
To order this 170+ pagereport, which features 55+ figures and 80+ tables, please visit this link
The USD 1.6 billion (by 2030) financial opportunity within thefragment-based drug discovery market has been analyzed across the followingsegments:
§ Type of ScreeningTechnique Used
§ X-ray Crystallography
§ Nuclear MagneticResonance
§ Surface PlasmonResonance
§ Other ScreeningTechniques
§ Type of Service Offered
§ Library Screening
§ Fragment Screening
§ Fragment Optimization
§ End User
§ Industry Players
§ Non-Industry Players
§ Key geographicalregions
§ North America (US andCanada)
§ Europe (UK, France,Germany, Spain, Italy, and rest of Europe)
§ Asia-Pacific (China,Japan, India, and rest of Asia-Pacific / rest of the world)
The Fragment-based Drug Discovery Market:Library and Service Providers, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ 2bind
§ Charles River Laboratories
§ ChemAxon
§ ComInnex
§ Creative Biolabs
§ Creative Biostructure
§ CRELUX
§ Domainex
§ Evotec
§ Red Glead Discovery
§ SARomics Biostructures
§ Shanghai ChemPartner
§ Sygnature Discovery
§ Vernalis Research
Table of Contents
Press Release:Variation 3 (Format 4)
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Profiles: Fragment-based Drug Discovery Library and ServiceProviders
6. Partnerships and Collaborations
7. Key Acquisition Targets
8. Company Competitiveness Analysis
9. Cost Saving Analysis
10. Market Forecast and Opportunity Analysis
11. Executive Insights
12. Concluding Remarks
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
Topurchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com